MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study

MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study

Objective: While PLD-Trabectedin is an approved treatment for relapsed platinum-sensitive ovarian cancer, its efficacy and tolerability has so far not been tested extensively in patients who progress after poly ADP-ribose polymerase inhibitor (PARPi) treatment. Methodology: This multicenter, retrosp...

Full description

Bibliographic Details
Main Authors: Margherita Turinetto, Andrea Ricotti, Claudia Marchetti, Carmela Pisano, Claudio Zamagni, Chiara Cassani, Paola Malaguti, Alessandra Baldoni, Paolo Scollo, Giuseppa Scandurra, Alessandro Parisi, Grazia Artioli, Innocenza Palaia, Laura Vertechy, Alice Bergamini, Elisa Picardo, Valentina Tuninetti, Giulia Scotto, Giovanni Scambia, Sandro Pignata, Giorgio Valabrega
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Cancers
Subjects:
ovarian cancer
PLD-Trabectedin
PARPi
platinum-sensitive disease
Online Access:https://www.mdpi.com/2072-6694/16/1/41

Internet

https://www.mdpi.com/2072-6694/16/1/41

Similar Items